Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa

Rhea-AI Summary

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announces CEO Gaurav Shah will present at the 2021 Cell & Gene Meeting on the Mesa in Carlsbad, CA, on Tuesday, October 12, at 2:15 p.m. PST. The presentation will be available via a live audio webcast for registered attendees, with a recorded version accessible within 24 hours. Rocket focuses on genetic therapies for rare childhood disorders, with programs targeting conditions such as Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis, utilizing both lentiviral vector and adeno-associated virus technologies.

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., chief executive officer, will deliver an in-person company presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference virtually and in Carlsbad, CA. The Rocket Pharmaceuticals presentation will take place on Tuesday, October 12 at 2:15 p.m. PST.

A live audio webcast of the presentation will be available to registered attendees within the virtual platform and within 24 hours of the Rocket presentation the video will be available for on-demand viewing.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005343/en/

Media

Kevin Giordano

Director, Corporate Communications

kgiordano@rocketpharma.com

Investors

Mayur Kasetty, M.D.

Director, Business Development & Operations

investors@rocketpharma.com

Source: Rocket Pharmaceuticals, Inc.

FAQ

When is Rocket Pharmaceuticals' CEO presenting at the Cell & Gene Meeting on the Mesa?

Gaurav Shah, CEO of Rocket Pharmaceuticals, will present on Tuesday, October 12, 2021, at 2:15 p.m. PST.

Where is the 2021 Cell & Gene Meeting on the Mesa being held?

The meeting is taking place in Carlsbad, CA, as a hybrid conference.

How can I access the Rocket Pharmaceuticals presentation?

The presentation will be available through a live audio webcast for registered attendees and can be viewed on-demand within 24 hours after the event.

What diseases does Rocket Pharmaceuticals focus on in its gene therapy programs?

Rocket Pharmaceuticals targets rare childhood disorders like Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.

What is the stock symbol for Rocket Pharmaceuticals?

The stock symbol for Rocket Pharmaceuticals is RCKT.